Pamidronate to Treat Osteogenesis Imperfecta in Children

PHASE3CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

June 30, 2000

Primary Completion Date

May 31, 2014

Study Completion Date

March 31, 2015

Conditions
Osteogenesis Imperfecta
Interventions
DRUG

Pamidronate (Aredia)

Patients receive a dose of 1mg/kg/cycle (3-day infusion = 1 cycle)

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
collaborator

National Institutes of Health Clinical Center (CC)

NIH

lead

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

NCT00005901 - Pamidronate to Treat Osteogenesis Imperfecta in Children | Biotech Hunter | Biotech Hunter